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Abstract
Background: The estimate of the prevalence of the most common chronic conditions (CCs) is calculated using
direct methods such as prevalence surveys but also indirect methods using health administrative databases.
The aim of this study is to provide estimates prevalence of CCs in Lazio region of Italy (including Rome), using the
drug prescription’s database and to compare these estimates with those obtained using other health
administrative databases.
Methods: Prevalence of CCs was estimated using pharmacy data (PD) using the Anathomical Therapeutic
Chemical Classification System (ATC).
Prevalences estimate were compared with those estimated by hospital information system (HIS) using list of ICD9-
CM diagnosis coding, registry of exempt patients from health care cost for pathology (REP) and national health
survey performed by the Italian bureau of census (ISTAT).
Results: From the PD we identified 20 CCs. About one fourth of the population received a drug for treating a
cardiovascular disease, 9% for treating a rheumatologic conditions.
The estimated prevalences using the PD were usually higher that those obtained with one of the other sources.
Regarding the comparison with the ISTAT survey there was a good agreement for cardiovascular disease, diabetes
and thyroid disorder whereas for rheumatologic conditions, chronic respiratory illnesses, migraine and Alzheimer’s
disease, the prevalence estimates were lower than those estimated by ISTAT survey. Estimates of prevalences
derived by the HIS and by the REP were usually lower than those of the PD (but malignancies, chronic renal
diseases).
Conclusion: Our study showed that PD can be used to provide reliable prevalence estimates of several CCs in the
general population.
Background
One of the most important aim of public health is to
provide an accurate evaluation of the population health
conditions, its need for care and related costs.
Usually, the estimate of prevalence for the most com-
mon chronic conditions (CCs) is calculated using direct
methods such as prevalence surveys [1] but also indirect
methods using health administrative databases that col-
lect this information for other reasons were used [2].
Ideally, prevalence surveys that estimate the preva-
lence of CCs by a clinical evaluation, and not only by
self-reported information from subjects should be per-
formed. However, they are expensive and when per-
formed were limited to elderly and in specific
geographical areas [3,4].
Prevalence surveys based on self-reported information
are regularly conducted in several countries to provide
estimates for several CCs [1,5]. Some of these surveys
present the advantage to be not particularly expensive
but, at the same time, they are criticized because the
presence/absence of the disease is self-referred and thus
conditioned by potential bias. Furthermore, these sur-
veys refer to a sample of the population and thus are
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any medium, provided the original work is properly cited.also limited by the sampling uncertainty. In particular,
these estimates could be biased because some indivi-
duals likely might not be reached by the survey (e.g.,
very old people living in retirement homes).
As far as the use of health administrative databases to
estimate the prevalence of some diseases, hospital dis-
charge registries are those more often used because they
collect specific information about diagnoses [6]. How-
ever, in some cases the accuracy of diagnostic code can
be low [7,8]; furthermore, for some diseases the prob-
ability of being hospitalized, also for a long period, is
very low and thus it might underestimate the actual
prevalence.
The health administrative database of the general
practitioners (GPs) has also been used to estimate pre-
valence given that for some conditions it is likely that a
subject with the studied disease may be in charge of the
GPs [9,10]. However, GPs are not formally requested to
collect specific databases with information about dis-
eases and they collect data quite exclusively for facilitat-
ing their routine management such as drug
prescriptions, doctor’s notes, et cetera. This means that
the quality about diagnosis may be heterogeneous;
furthermore, for some CCs, GP has likely very few con-
tacts with the patients; finally, at least for Italy, the
access by public health services to GP’s databases is
impossible given that there are no statutory compliances
for that.
Recently, the use of drug prescription database has
been proposed to estimate the prevalence of specific
CCs [11,12]. This can be done when the drug prescrip-
tions are unambiguously used for the treatment of these
diseases (e.g., insulin for diabetes mellitus). In Italy drug
prescriptions are collected at regional level and the cov-
erage is expected to be extremely high because they are
used for reimbursement by the regional health service
(RHS).
The objective of this study is to provide estimates of
prevalences of people diagnosed with several CCs in
Lazio region, Italy, in 2006 using the drug prescription’s
database and to compare these estimates with those
obtained using other health administrative databases.
These prevalence estimates were also compared, when
possible, with that reported by the survey performed in
2004-2005 by the Italian bureau of census (ISTAT) [1].
Methods
Context
All Italian citizens are enrolled in the National Health
Service (NHS) [13-15] which provides health care free
of charge. This entails that for administrative reasons
several registries collecting information on use of health
services reimbursed by each regional HS are needed. As
far as our objective, there are three administrative
archives of interest: one contains all outpatient drug
prescriptions; another contains all the citizens exempts
for the health expenses because affected by important
diseases; the third one collects all discharges from
hospitals.
Setting
Lazio is a region of central Italy (including Rome) with a
population of around 5,300,000 at the end of 2006 cen-
sus [16] and, as well as all the other Italian regions, it
provides its citizens with a universal coverage for health
care.
Data sources
Regional informative system on drugs (pharmacy data)
The Italian National Health System (NHS) provides
medications to the population through the National
Therapeutic Formulary (NTF) [17]. Lazio region has an
informative system collecting all relevant data (i.e.,
patients’ demographics information, the tax code, drug
code, dose, formulation, number of packages, date of
prescription) about prescribed drugs by GPs and public
ambulatories, belonging to a list called “drugs in class
A” of the NTF. Drugs for CCs treatments might be
totally or partially reimbursed by the RHS and are often
subject to restrictive note (in Italian called “Nota CUF”)
for dispensing defined by the Italian Medicine Agency
(AIFA - Agenzia Italiana Farmaco) [18]. These restric-
tions can be considered as guidelines for a more appro-
priate use of pharmaceuticals. The “Nota CUF” defines
the CC for dispensing the drug and increased our ability
to capture drug users affected by the selected CCs.
Drugs are classified by ATC groups, according to the
World Health Organization (WHO) Anatomical Thera-
peutic Chemical (ATC) classification system [19].
Drugs dispensed directly by the hospitals are not
included in this informative system.
Regional Hospital informative system (HIS)
All hospitals are required to record data on standardized
form about admission and discharge dates, patients
demographic data (i.e., date of birth, gender, name, sur-
name, municipality of residence, nationality, tax code),
the principal diagnosis and up to five secondary diag-
noses [coded by the International Classification of Dis-
eases - ninth revision (ICD-9)], diagnostic procedures
(also coded by the ICD-9), and death, if occurred during
the hospitalization.
Registry of exempt patients from health care cost for
pathology (REP)
The RHS requires that for some CCs it is needed to
have a recognized diagnosis by the local health unit for
having free access to health care services (e.g., drugs,
laboratory and diagnostic visits). There is a regional reg-
istry containing demographic data of the patients with
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the date of request for exemption.
ISTAT Health survey 2004-2005
This survey considered a probabilistic sample of more
than 50,000 Italian families (3096 families and 7322 sub-
jects in Lazio region). Using a face-to-face standardized
questionnaire, it evaluated several aspects of health
including the awareness of being affected by one or
more CCs for the non-institutionalized population. The
questionnaire is divided in several sections: health con-
ditions, drug consumption, prevention, life styles and
use and opinion of health services. The survey provided
estimates prevalence rates of selected diseases [1].
Identifying individuals with CCs through pharmacy data
To detect subjects with specific CCs, we selected only
those with at least one prescription of a drug unambigu-
ously used for the treatment of that CCs. More specifi-
cally, for each CCs we referred to those ATC codes
already proposed for the Italian context in another study
(table 1) [11,12,20]. To limit potential unforeseen short-
term use, we restricted our selection to individuals who
had prescribed at least one drug belonging to the speci-
fic list of drugs identifying the CCs and with at least
three packages during the year 2006.
Identifying individuals with CCs in the HIS
We identified subjects with CCs using ICD9-CM diag-
nosis coding and we used the list proposed by Romano
et al. [21]. Given that the probability to be recovered
with some of the CCs in one year could be low, we
referred to hospital discharges in Lazio region reported
in the period 2002-2006 and not only to the year 2006
as done for the other sources.
Prevalence estimates
For each source used, subjects with each specific CCs were
counted using a anonymous code (a string that is a unique
identifier for each individual). To estimate prevalence of
CCs obtained with the different data sources we used as
denominator the population living in Lazio region as esti-
mated at 1/1/2007 by the bureau of census [16]. We also
provided estimates stratified by sex. Analyses were per-
formed using SAS 9.2 and STATA 11.0. Regarding esti-
mates from the ISTAT survey (clustered-two stage-sample
of Italian families stratified by municipality), prevalence of
chronic conditions and 95% confidence intervals (95%CI)
were calculated using the “svyset” (defines the survey
design for dataset) and “svytab” (calculates the absolute
and the relative frequency taking into account the survey
data) STATA commands [22].
Results
From pharmacy data we identified drugs specific for 20
CCs (table 1). In 2006, about 2.5 million people (48% of
the entire population) had prescribed reimbursed drugs
for one or more of these CCs; these people were about
the 72% of the individuals who had prescribed at least
one drug reimbursed by the regional health system.
All drugs identifying the 20 CCs represented 61% of
t h ee n t i r ev o l u m eo fp a c k a g e s .D r u ge x p e n d i t u r ef o r
these 20 CCs was about eight hundred million of euro,
corresponding to 57% of the total expenditure (data not
shown).
Table 2 shows the number of subjects, the estimated
prevalences, the volumes of prescriptions, the mean
annual cost per individual for treatment, and the total
cost. About 23% of the population received a drug for
treating a cardiovascular disease, 9% for treating a rheu-
matologic conditions and then diminishing for other
CCs. Table 3 compares the estimates of prevalences of
the 20 CCs identifiable by the pharmacy data with those
estimated by the ISTAT survey of 2005 and those
obtained using the HIS and the REP, while the Figure 1
(A) and 1(B) show the estimates of prevalences by sex
using the four different sources.
The estimated prevalences using the pharmacy data
were usually higher than that obtained with one of the
other sources. For thirteen CCs at least one of the other
sources provided higher estimates; using an arbitrary
cut-off of +15% in the relative difference between phar-
macy data estimates and the maximum of the estimates
from the other sources (last column of table 3), for 12
CCs the estimates were more greater than those
obtained using the pharmacy data. It is of note that for
1 1C C st h er e l a t i v ed i f f e r e n c ew a sh i g h e rm o r et h a n
50% of that obtained with the pharmacy data.
Regarding the comparison with the ISTAT survey it is
of a good agreement for cardiovascular disease, diabetes
and thyroid disorder whereas for seven CCs (i.e., rheu-
matologic conditions, chronic respiratory illnesses, psy-
chiatric diseases, Paget’s disease or other osteoporoses,
migraine, Alzheimer’s disease, and cirrhosis) the preva-
lence estimates were 70% or more higher than those
obtained by the pharmacy data. Estimates of prevalences
were usually lower than those of the pharmacy data
when derived by the HIS (but malignancies, Alzheimer’s
disease, chronic renal diseases, HIV/AIDS and cirrhosis)
and by the REP (but malignancies, chronic renal dis-
eases, and chronic hepatitis and selective malignancies).
Also stratifying by sex there were similar results.
Discussion
This study evaluated the possible use of pharmacy data
on identifying individuals with several CCs in Lazio
region, Italy.
We found that the highest prevalences of people diag-
nosed with CCs were for cardiovascular diseases and
rheumatologic conditions. These results are coherent
with previous estimates in analogous studies performed
in another Italian region and in US [10,23]. The
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pharmacy data provided reliable estimates for diseases
particularly impacting the health and social services
such as Parkinson and Alzheimer disease. Prevalence
estimates of these diseases using pharmacy data were
comparable to those found in other European studies
[24-26].
Data were then compared in terms of prevalence with
other health administrative databases and with preva-
lence estimates obtained by the ISTAT survey. Assum-
ing that all sources correctly identified each specific
CCs, we observed that for several of these CCs the phar-
macy data was better on identifying cases. This was
particularly pronounced with respect to the HIS and to
the REP that only in few cases provided higher estimates
than the pharmacy data. With respect to the prevalence
estimates by the ISTAT survey we highlighted that for
some CCs the prevalences estimated by the pharmacy
data had a quite good level of agreement (i.e., cardiovas-
cular diseases, diabetes, thyroid disorders, malignancies,
cirrhosis). For rheumatologic conditions, chronic
respiratory illnesses, psychiatric diseases, osteoporosis,
migraine the agreement was very low and the ISTAT
survey provided extremely higher estimates of preva-
lences compared to those obtained with the pharmacy
data.
Table 1 Chronic conditions (CCs), associated medications and ATC codes.
Chronic Disease Drug Descriptions ATC Codes
Alzheimer’s Anticholinesterase agents N06DA; N06DX
Digitalis glycosides, antiarrhythmics, diuretics, beta-adrenergic C01AA; C01BA; C01BB; C01BC; C01BD; C01DA;
Cardiovascular diseases blockers, alpha blockers, ACE inhibitors, calcium channel C02AB; C02AC;C02CA; C03AA; C03BA; C03CA;
blockers, antihypertensive vasodilators C03CX; C03DA; C03EA; C03EB; C07AA; C07AB;
Chronic hepatitis Interferons* L03AB
Chronic renal disease Agents for hyperkalaemia and hyperphosphataemia V03AE; B03XA
Chronic respiratory illnesses Inhaled corticosteroids, beta-2-adrenoreceptor agonist, R03AC; R03AK; R03BA; R03BB; R03BC; R03CC;
xanthines, leucotriene antagonists, cromolyn R03DA; R03DC
Cirrhosis Blood substitutives and plasmatic protein fractions* B05AA; B02BA
Crohn’s and ulcerative colitis Intestinal corticosteroid agents A07EA; A07EC
A10AB; A10AC; A10AD; A10AE; A10BA; A10BB;
Diabetes Insulins, biguanides, sulphonylureas A10BD; A10BG; A10BX
N03AA; N03AB; N03AD; N03AE; N03AF; N03AG;
Epilepsy Anticonvulsivant barbiturates and congeners N03AX
Sympaticomimetic agents*, parasympaticomimetic
Glaucoma agents, anhydrase inhibitors*, ophthalmic beta blockers S01EA; S01EB; S01EC; S01ED; S01EE; S01EX
HIV/AIDS Nucleosides and nucleotides*, reverse transcriptase inhibitors J05AB; J05AD; J05AF
A04AA; H01CB; L01AA; L01AB; L01AX; L01BA;
L01BB; L01BC; L01DB; L01XB; L01XX; L02AB;
Malignancies Antineoplastics, 5HT3 antagonists* L02AE; L02BA; L02BB; L02BG; L03AA; L03AX;
R05DA; R05DB27
Migraine Ergot alkaloids, 5HT1 agonists N02CA; N02CC; N02CX
Paget’s disease/other H05AA02; H05AA03; H05BA; M05BA; M05BB;
osteoporosis chronic Bisphosphonates*, calcitonin* G03XC01; M05BX; A12AA; A12AX
conditions
Parkinson’s Dopamine, MAO b inhibitors N04AA; N04AB; N04BA; N04BC; N04BX
Psoriasis Oral and topical antipsoriasis agents D05AX; D05BB
N05AA; N05AB; N05AC; N05AD; N05AF; N05AG;
Psychiatric disorders Antidepressants, antipsychotics agents N05AH; N05AL; N05AN; N05AX; N05BA; N05AA;
N06AB; N06AX
M01AB; M01AC; M01AE; M01AG; M01AH; M01AX;
Rheumatological conditions Anti-inflammatory non-steroids*, gold salts, aminoquinolines M01CB; M01CC; P01BA
Thyroid disorders Thyroid replacement, antithyroid agents H03AA; H03BB; H03BC
Tuberculosis Antituberculosis antibiotics*, isoniazid J04AB; J04AC; J04AK; J04AM
*drug subject to ‘Nota’ CUF (see methods section)
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pharmacy data and ISTAT survey is that the latter mea-
sured the self reported CCs and several studies suggested
that the accuracy of self-reporting can be low for some
CCs. As an example, it has been shown that subjects over-
report rheumatologic conditions in surveys where the
diagnosis is self-reported [27,28]. Furthermore, self-report-
ing accuracy is likely to be very low for CCs with a vague
definition such as mig r a i n e .O t h e r w i s e ,i ti sl i k e l yt h a t
those treated (and then identified with pharmacy data) are
likely to refer to a more severe case definition.
The HIS is likely less sensitive because it identifies
only the more severe cases that need hospitalization.
Also the REP is likely less sensitive due to the fact that
t h ef r e ea c c e s st oh e a l t hc a r es e r v i c e si sa l s og i v e nt o
citizens belonging to specific groups of age (e.g., people
aged ≥ 65 years old) or of low income and thus there is
no practical reason in some cases to require the exempt
for a specific CCs.
Some CCs prevalences were comparable with those
estimated by an Italian health administrative database of
GPs [10]. For this source there were no available data of
CCs at regional level, but our findings showed a good
agreement with some Italian prevalence of CCs, particu-
larly with diabetes [29] and chronic obstructive pulmon-
ary disease [10].
The prevalence estimates obtained by pharmacy data
have several advantages compared to those obtained by
other health administrative databases and by cross-sec-
tional surveys.
The prevalence estimates can be easily obtained and
they provide estimates not conditioned by sampling
problems.
In particular, these estimates can be provided also by
very small geographical areas while this is not possible
in surveys planned to provide reliable information, in
terms of precision, only at a national or regional level.
Furthermore, these estimates can be updated frequently.
Another advantage is that the ATC coding used to iden-
tify CCs is internationally used and this allows immedi-
ate comparisons of prevalence estimates in other
countries. Finally, it is important to highlight that phar-
macy data could also be used to evaluate the incidence
for some acute diseases in case a specific treatment
would be available.
Limitations
The present study has several limitations. All the health
databases used are affected by selection bias because
they likely do identify more severe cases. Statistical tech-
niques had been proposed to correct for the selection
bias using external information [30] such as health
Table 2 Number of individuals with identified 20 chronic conditions (CCs), reimbursed prescribed drugs and
associated costs.
Cost per
Prevalence patient Total Cost
Chronic Condition Individuals (per 1000) Packages (€)( €)
Cardiovascular diseases 1199325 226.1 35,052,888 323.8 388,332,400
Rheumatologic conditions 463439 87.4 3,544,925 62.6 28,991,584
Chronic respiratory illnesses 251500 47.4 3,093,147 315.0 79,233,729
Diabetes 234117 44.1 4,565,308 192.6 45,100,938
Thyroid disorders 232852 43.9 1,906,099 23.5 5,477,555
Psychiatric diseases 202575 38.2 2,832,875 289.5 58,636,881
Epilepsy 99997 18.9 1,836,803 262.6 26,261,613
Paget’s disease/osteoporosis chronic conditions 97167 18.3 991,775 262.8 25,532,022
Glaucoma 87793 16.5 1,571,032 229.2 20,120,303
Malignancies 77791 14.7 1,008,838 1,073.0 83,468,370
Parkinson’s disease 23836 4.5 634,129 579.2 13,805,687
Crohn’s and Ulcerative colitis 20763 3.9 384,769 416.5 8,647,390
Migraine 20354 3.8 349,518 382.9 7,794,343
Psoriasis 11735 2.2 156,922 180.1 2,113,543
Alzheimer’s disease 8220 1.5 93,896 1,174.8 9,656,930
HIV/AIDS 5170 1.0 54,470 703.1 3,635,284
Chronic renal diseases 4271 0.8 60,225 2,218.3 9,474,249
Cirrhosis 3989 0.8 87,385 443.1 1,767,496
Chronic hepatitis and selective malignancies 2633 0.5 77,672 6,058.6 15,952,232
Tuberculosis 2093 0.4 32,552 113.3 237,101
Lazio region, Italy.
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because the non-availability of survey data. Another
approach to correct for selection bias is using capture-
recapture techniques [31] but we were not authorized to
link the health databases due to privacy reasons.
Using pharmacy data to identify a specific CC implies
that those drugs are used exclusively for the treatment
of that CC. Furthermore, it is also important that the
drug identifying CCs be used in any stage of the disease.
We feel that for some CCs the coverage of drug treat-
ment is low and hence a poor proxy for prevalence (i.e.,
anticholinesterase agents for dementia, interferons for
chronic hepatis B, drugs listed for chronic renal disease,
for cirrhosis, and for malignancies). It is also important
to remind that for some diseases, such as osteoporosis
and diabetes, the pharmacological treatment is not given
mainly because of under-diagnosis of the conditions.
Another limit regards the potential inclusion of indivi-
duals without the specific CC evaluated who used the
drug as incidental users or for other CCs not considered
in this study. However, this limit has had little impact
because we referred to drugs that had restrictive notes
for dispensing, restricting the use only to individuals
diagnosed with that CCs (see methods section). Further-
more, we included only individuals who had prescribed
t h r e eo rm o r ep a c k a g e so fd r u gu s e dt oi d e n t i f yt h e
CCs, but no sensitivity analysis was performed to deter-
mine if increasing the number of packages resulted in
substantial changes in the prevalence estimates.
Finally, this study did not consider drugs directly pre-
scribed/administered in hospital setting.
Conclusions
Our study showed that pharmacy data can provide, in
several cases, reliable prevalence estimates of CCs in the
general population. The estimates obtained could be a
quick and priceless alternative to survey data that assess
the health population status.
Table 3 Estimates of prevalence per 1000 for 20 chronic conditions (CCs) using different sources.
Chronic Condition Prevalence
Pharmacy
Data 2006 (a)
Prevalence
Hospital
Discharge 2002-
06 (b)
Prevalence
Registry of
Exempt 2006 (c)
National
Health
Survey 2005
(d)
95% CI Relative difference between
pharmacy data and other
sources (%) #
Cardiovascular diseases 226.1 62.9 107.6 201.4 190.8 - 209.1 -10.9
Rheumatologic
conditions
(inflammations,
arthritis, etc.)
87.4 2.6 1.7§ 183.3 173.8 - 193.3 109.8
Chronic respiratory
illnesses (asthma,
COPD, etc.)
47.4 28.8 10.1 88.9 82.5 - 95.5 87.5
Migraine 3.8 n.a. n.a. 79.7 72.9 - 87.0 1977.2
Psychiatric diseases 38.2 n.a. 3.0* 69.0 63.1 - 74.8 80.7
Paget’s disease/other
osteoporosis chronic
conditions
18.3 n.a. 0.1** 57.3 51.8 - 63.4 212.8
Diabetes 44.1 34.0 52.6 48.0 42.9 - 53.7 19.2
Thyroid disorders 43.9 n.a. 29.4 45.4 40.4 - 51.0 3.4
Malignancies 14.7 39.1 42.0 11.4 8.9 - 14.5 186.1
Epilepsy 18.9 n.a. 2.5 n.a. -87.0
Glaucoma 16.5 n.a. 6.7 n.a. -59.7
Chronic renal diseases 0.8 8.6 4.8 n.a. 968.2
Chronic hepatitis and
selective malignancies
0.5 n.a. 5.1 n.a. 922.3
Parkinson’s disease 4.5 n.a. 1.2 1.9 1.0 - 3.4 -57.7
Alzheimer’s disease 1.5 5.4° 0.4 4.0 2.7 - 6.0 158.1
Crohn’s and Ulcerative
colitis
3.9 n.a. 2.1 n.a. -45.6
Psoriasis 2.2 n.a. 2.0 n.a. -7.7
HIV/AIDS 1.0 1.5 0.8 n.a. 53.9
Cirrhosis 0.8 1.0 1.1 1.3 0.7 - 2.4 76.9
Tuberculosis 0.4 n.a. 0.3 n.a. -19.5
Lazio region, Italy.
NA: not available or not estimable; °any type of dementia; § only rheumatoid arthritis; *excluded anxiety and depression; **only Paget’sd i s e a s e ;
# [(max(b,c,d)-a)/a
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Page 6 of 8Figure 1 (A-B): Estimates of prevalence per 1000 by sex for 20 chronic conditions (CCs) using different sources. Lazio region, Italy.
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comparison of disease prevalence, prescribing and drug
costs in managing CCs.
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